We are live on ! Find out more
DTIL icon

Precision BioSciences
DTIL

132 hedge funds and large institutions have $337M invested in Precision BioSciences in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $2.17M | Put options by funds: $1M

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

19% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 36

2% more funds holding

Funds holding: 130 → 132 (+2)

0.03% less ownership

Funds ownership: 1.67% → 1.63% (-0.03%)

6% less capital invested

Capital invested by funds: $357M → $337M (-$20.5M)

Holders
132
Holders Change
+2
Holders Change %
+1.54%
% of All Funds
2.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
43
Reduced
36
Closed
14
Calls
$2.17M
Puts
$1M
Net Calls
+$1.17M
Net Calls Change
+$104K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$4.45M
2
JP Morgan Chase
JP Morgan Chase
New York
+$4.34M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.67M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.39M
5
N
Nuveen
North Carolina
+$3.34M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.47M
2
Morgan Stanley
Morgan Stanley
New York
-$4.29M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.12M
4
State Street
State Street
Massachusetts
-$2.86M
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$2.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lazard Asset Management
101
Lazard Asset Management
New York
$99K +$19.7K +58 +25%
OSAM
102
O'Shaughnessy Asset Management
Connecticut
$81K +$79.3K +234 New
Simplex Trading
103
Simplex Trading
Illinois
$69K – – –
TRCT
104
Tower Research Capital (TRC)
New York
$62K +$24.7K +73 +69%
CAM
105
Close Asset Management
United Kingdom
$58K +$56.6K +167 New
Macquarie Group
106
Macquarie Group
Australia
$55K +$53.9K +159 New
AIP
107
Ameritas Investment Partners
Nebraska
$47K – – –
US Bancorp
108
US Bancorp
Minnesota
$37K +$1.02K +3 +3%
Canada Life
109
Canada Life
Manitoba, Canada
$24K – – –
PHK
110
Point72 Hong Kong
Hong Kong
$22K +$21.7K +64 New
Baillie Gifford & Co
111
Baillie Gifford & Co
United Kingdom
$17K +$7.12K +21 +75%
PCM
112
Penserra Capital Management
California
$15K +$339 +1 +2%
JMF
113
Johnson Midwest Financial
Iowa
$10K – – –
SIS
114
Sound Income Strategies
Florida
$9K – – –
CFA
115
Carroll Financial Associates
North Carolina
$6K – – –
TWA
116
TCI Wealth Advisors
Arizona
$6K – – –
LWANC
117
Laurel Wealth Advisors (North Carolina)
North Carolina
$5K – – –
LC
118
Lindbrook Capital
California
$5K – – –
FDCDDQ
119
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.21K – – –
PNC Financial Services Group
120
PNC Financial Services Group
Pennsylvania
$4K – – –
RE
121
RBC Europe
United Kingdom
$3.47K – – –
Koshinski Asset Management
122
Koshinski Asset Management
Illinois
$3.46K +$3.39K +10 New
S
123
SignatureFD
Georgia
$2K – – –
TFA
124
Toth Financial Advisory
Virginia
$2K – – –
Daiwa Securities Group
125
Daiwa Securities Group
Japan
$2K +$1.02K +3 +75%
2 3 4
5
6

DTIL Hedge Fund Activity: Q3 2021 in Review

132 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q3 2021, worth a combined $337M — down 5.7% from $357M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DTIL positions and 14 closed out — a net gain of 4 holders — while 43 added to existing stakes and 36 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $4.45M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $7.47M sold.

  • 132 institutional investors held Precision BioSciences (DTIL) as of Q3 2021, up from 130 in Q2 2021.
  • Funds reported $337M of Precision BioSciences stock for Q3 2021, down 5.7% quarter-over-quarter.
  • 18 funds opened new Precision BioSciences positions in Q3 2021 and 14 closed out, a net change of +4 holders.
  • The largest Precision BioSciences buyer in Q3 2021 was Goldman Sachs, an estimated $4.45M added.
  • The largest Precision BioSciences seller in Q3 2021 was T. Rowe Price Associates, an estimated $7.47M sold.

Based on aggregated 13F filings for Q3 2021.